Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding

Aaron Trimble, Cameron McKinzie, Mary Terrell, Elizabeth Stringer, Charles R. Esther

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

With the growing class of CFTR modulator therapy available to more patients and with increasing pregnancies in individuals with CF, there is a growing need to understand the effects of these agents during pregnancy. There are few reports of their continued use in the literature, although it is likely that this is not an uncommon occurrence. We report the uncomplicated and successful pregnancy of a woman treated with lumacaftor/ivacaftor, as well as the clinical course of the infant during the first 9 months of life. We also report drug levels in plasma from the mother, cord blood, breast milk, and infant to estimate fetal and infant drug exposure.

Original languageEnglish (US)
Pages (from-to)779-782
Number of pages4
JournalJournal of Cystic Fibrosis
Volume17
Issue number6
DOIs
StatePublished - Nov 2018
Externally publishedYes

Keywords

  • CFTR modulators
  • Ivacaftor
  • Lumacaftor
  • Pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding'. Together they form a unique fingerprint.

Cite this